PE20190840A1 - Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e - Google Patents
Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad eInfo
- Publication number
- PE20190840A1 PE20190840A1 PE2019000824A PE2019000824A PE20190840A1 PE 20190840 A1 PE20190840 A1 PE 20190840A1 PE 2019000824 A PE2019000824 A PE 2019000824A PE 2019000824 A PE2019000824 A PE 2019000824A PE 20190840 A1 PE20190840 A1 PE 20190840A1
- Authority
- PE
- Peru
- Prior art keywords
- molecules
- cause
- major histocompatibility
- histocompatibility complex
- cells restricted
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 241000701022 Cytomegalovirus Species 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title 1
- 108700011259 MicroRNAs Proteins 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revelan vectores de CMV que carecen de proteinas UL128, UL130, UL146 y UL147 activas que tambien pueden comprender uno o mas elementos reguladores de microARN (MRE) que restringen la expresion del CMV. La inmunizacion con los vectores de CMV revelados permiten la seleccion de diferentes respuestas de las celulas T CD8+ - celulas T CD8+ restringidas por MHC-Ia, MHC-II, o MHC-E
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662409840P | 2016-10-18 | 2016-10-18 | |
PCT/US2017/057106 WO2018075591A1 (en) | 2016-10-18 | 2017-10-18 | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190840A1 true PE20190840A1 (es) | 2019-06-17 |
Family
ID=62018862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019000824A PE20190840A1 (es) | 2016-10-18 | 2017-10-18 | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e |
Country Status (22)
Country | Link |
---|---|
US (2) | US10532099B2 (es) |
EP (1) | EP3529363A4 (es) |
JP (2) | JP2019531745A (es) |
KR (1) | KR102604486B1 (es) |
CN (1) | CN110036112B (es) |
AU (1) | AU2017346788A1 (es) |
BR (1) | BR112019007982A2 (es) |
CA (1) | CA3040303A1 (es) |
CL (1) | CL2019001054A1 (es) |
CO (1) | CO2019004102A2 (es) |
CR (1) | CR20190205A (es) |
DO (1) | DOP2019000086A (es) |
EA (1) | EA201990937A1 (es) |
EC (1) | ECSP19031754A (es) |
IL (1) | IL266011B2 (es) |
MA (1) | MA46588A (es) |
MX (1) | MX2019004518A (es) |
PE (1) | PE20190840A1 (es) |
SG (1) | SG11201903340TA (es) |
TN (1) | TN2019000124A1 (es) |
UA (1) | UA126860C2 (es) |
WO (1) | WO2018075591A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE037227T2 (hu) | 2010-05-14 | 2018-08-28 | Univ Oregon Health & Science | Rekombináns HCMV és RHCMV vektorok és alkalmazásuk |
PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
AU2014225886B2 (en) | 2013-03-05 | 2020-04-16 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
UA120938C2 (uk) | 2014-07-16 | 2020-03-10 | Орегон Хелс Енд Сайєнс Юніверсіті | Цитомегаловірус людини, що містить екзогенний антиген |
MA41756A (fr) | 2015-02-10 | 2017-12-20 | Fruh Klaus | Procédés et compositions utiles dans la génération de réponses non canoniques de lymphocytes t cd8+ |
CA3005136A1 (en) | 2015-11-20 | 2017-05-26 | Oregon Health & Science University | Cmv vectors comprising microrna recognition elements |
BR112019007982A2 (pt) * | 2016-10-18 | 2019-07-02 | Univ Oregon Health & Science | vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal |
US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
CN114025792A (zh) * | 2019-03-21 | 2022-02-08 | 21C生物公司 | 针对感染期间的致病性免疫激活细胞的疫苗 |
US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
CN113950334A (zh) * | 2019-06-07 | 2022-01-18 | 俄勒冈健康与科学大学 | 乙型肝炎病毒特异性t细胞应答 |
CN114206385A (zh) * | 2019-06-07 | 2022-03-18 | 俄勒冈健康与科学大学 | 肿瘤相关抗原特异性t细胞应答 |
AU2020334061A1 (en) | 2019-08-20 | 2022-03-10 | Oregon Health & Science University | Modulation of T cell responses by UL18 of human cytomegalovirus |
EP4076510A4 (en) * | 2019-12-16 | 2024-01-10 | Univ Oregon Health & Science | MULTI-SPECIFIC T-CELL RECEPTORS |
WO2023034783A1 (en) | 2021-08-31 | 2023-03-09 | Vir Biotechnology, Inc. | Tuberculosis vaccines |
TW202311531A (zh) | 2021-08-31 | 2023-03-16 | 美商維爾生物科技股份有限公司 | 重組hcmv載體及其用途 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
EP0319570B1 (en) | 1987-06-26 | 1995-02-22 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene and use thereof |
SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
AU7192394A (en) | 1993-07-19 | 1995-02-20 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
AU2234995A (en) | 1994-04-29 | 1995-11-29 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
US6287557B1 (en) | 1995-02-21 | 2001-09-11 | Cantab Pharmaceuticals Research Limited | Methods of gene therapy using herpes viral vectors expressing GM-CSF |
CA2217297A1 (en) | 1995-04-04 | 1996-10-10 | Cell Genesys, Inc. | Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface |
WO1998004285A1 (en) | 1996-07-31 | 1998-02-05 | Ortho Pharmaceutical Corporation | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
EP1364037A4 (en) | 2001-02-02 | 2005-08-03 | Chemocentryx Inc | METHODS AND COMPOSITIONS USEFUL IN STIMULATING AN IMMUNE RESPONSE |
CA2438322A1 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
CA2461056A1 (en) | 2001-09-20 | 2003-03-27 | Glaxo Group Limited | Hiv-gag codon-optimised dna vaccines |
US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
EP1497412A4 (en) | 2002-04-30 | 2006-11-22 | Avior Therapeutics Inc | ADENOVIRUS VECTORS FOR IMMUNOTHERAPY |
DE10232322A1 (de) * | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
WO2005012545A2 (en) | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
CA2567597C (en) | 2004-05-25 | 2014-03-18 | Oregon Health And Science University | Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors |
EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
WO2006004661A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
EP1888622A1 (en) | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
BRPI0615400A2 (pt) | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
WO2008112146A2 (en) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
EP2167130A2 (en) | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
KR101241486B1 (ko) | 2007-10-30 | 2013-03-15 | 제넨테크, 인크. | 양이온 교환 크로마토그래피에 의한 항체 정제 |
CA2754826A1 (en) | 2009-03-06 | 2010-09-10 | Mount Sinai School Of Medicine | Live attenuated influenza virus vaccines comprising microrna response elements |
EP2424571B1 (en) * | 2009-04-30 | 2020-04-08 | Ospedale San Raffaele S.r.l. | Gene vector |
BR112012015523A2 (pt) | 2009-12-23 | 2017-04-18 | 4-Antibody Ag | membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv. |
US20120289760A1 (en) | 2010-01-27 | 2012-11-15 | Hill Ann B | Cytomegalovirus-based immunogenic preparations |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
JP2013527758A (ja) | 2010-05-05 | 2013-07-04 | ティリオン,クリスティアン | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
HUE037227T2 (hu) * | 2010-05-14 | 2018-08-28 | Univ Oregon Health & Science | Rekombináns HCMV és RHCMV vektorok és alkalmazásuk |
PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
WO2013040320A1 (en) | 2011-09-16 | 2013-03-21 | Oregon Health & Science University | Methods and kits used in identifying microrna targets |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
WO2014089158A1 (en) | 2012-12-04 | 2014-06-12 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
AU2014225886B2 (en) | 2013-03-05 | 2020-04-16 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
UA120938C2 (uk) | 2014-07-16 | 2020-03-10 | Орегон Хелс Енд Сайєнс Юніверсіті | Цитомегаловірус людини, що містить екзогенний антиген |
EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
MA41756A (fr) | 2015-02-10 | 2017-12-20 | Fruh Klaus | Procédés et compositions utiles dans la génération de réponses non canoniques de lymphocytes t cd8+ |
CA3005136A1 (en) | 2015-11-20 | 2017-05-26 | Oregon Health & Science University | Cmv vectors comprising microrna recognition elements |
US11091775B2 (en) * | 2016-06-22 | 2021-08-17 | Oregon Health And Science University | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
CA3028002A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
BR112019007982A2 (pt) * | 2016-10-18 | 2019-07-02 | Univ Oregon Health & Science | vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal |
-
2017
- 2017-10-18 BR BR112019007982A patent/BR112019007982A2/pt unknown
- 2017-10-18 WO PCT/US2017/057106 patent/WO2018075591A1/en active Application Filing
- 2017-10-18 CA CA3040303A patent/CA3040303A1/en active Pending
- 2017-10-18 JP JP2019520801A patent/JP2019531745A/ja active Pending
- 2017-10-18 UA UAA201904893A patent/UA126860C2/uk unknown
- 2017-10-18 CR CR20190205A patent/CR20190205A/es unknown
- 2017-10-18 MA MA046588A patent/MA46588A/fr unknown
- 2017-10-18 AU AU2017346788A patent/AU2017346788A1/en active Pending
- 2017-10-18 KR KR1020197013148A patent/KR102604486B1/ko active IP Right Grant
- 2017-10-18 SG SG11201903340TA patent/SG11201903340TA/en unknown
- 2017-10-18 CN CN201780064422.7A patent/CN110036112B/zh active Active
- 2017-10-18 TN TNP/2019/000124A patent/TN2019000124A1/en unknown
- 2017-10-18 MX MX2019004518A patent/MX2019004518A/es unknown
- 2017-10-18 EP EP17862978.8A patent/EP3529363A4/en active Pending
- 2017-10-18 EA EA201990937A patent/EA201990937A1/ru unknown
- 2017-10-18 PE PE2019000824A patent/PE20190840A1/es unknown
- 2017-10-18 IL IL266011A patent/IL266011B2/en unknown
- 2017-10-18 US US15/786,847 patent/US10532099B2/en active Active
-
2019
- 2019-04-08 DO DO2019000086A patent/DOP2019000086A/es unknown
- 2019-04-17 CL CL2019001054A patent/CL2019001054A1/es unknown
- 2019-04-24 CO CONC2019/0004102A patent/CO2019004102A2/es unknown
- 2019-05-07 EC ECSENADI201931754A patent/ECSP19031754A/es unknown
- 2019-11-26 US US16/696,403 patent/US11305015B2/en active Active
-
2022
- 2022-10-21 JP JP2022169043A patent/JP7478794B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190840A1 (es) | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e | |
CO2020006900A2 (es) | Medios y método para preparar vectores virales y usos de los mismos | |
CL2017000855A1 (es) | Inmunomoduladores | |
UY36400A (es) | Péptidos macrocíclicos como inhibidores de las interacciones entre las proteínas pd-1/pd-l1 y cd80/pd-l1 y sus funciones inmunomoduladoras | |
CO2019000395A2 (es) | Genes de mini–distrofina optimizados y casetes de expresión y su uso | |
AR105053A1 (es) | Inmunomoduladores | |
PH12017500441A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions | |
DK3488414T3 (da) | System og apparat til klinisk beslutningsoptimering | |
MX2017011960A (es) | Inmunomoduladores. | |
MX2017007677A (es) | Inmunomoduladores. | |
DK3307734T3 (da) | Nukleære receptormodulatorer (ror) til behandling af inflammatoriske og autoimmune sygdomme | |
CL2019002605A1 (es) | Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas. | |
DK3625236T3 (da) | Fremgangsmåde til fremstilling af et optisk aktivt cineolderivat | |
DK3548383T3 (da) | System og fremgangsmåde til fortøjning af et luftskib, dermed udstyret luftskib og dermed udstyrede modtagestrukturer | |
CL2018001799A1 (es) | Elementos estructurados y metodos de uso | |
DK3385683T3 (da) | Vejesystem | |
NO20171704A1 (en) | Multiplexed microvolt sensor systems | |
DK3296385T3 (da) | Modulopbygget fotobioreaktorsystem til algedyrkning | |
EP3193412A4 (en) | Fiber laser system and method for outputting laser beam | |
GB201400727D0 (en) | Beam focusing and accelerating system | |
MX2020004133A (es) | Oligosacaridos inmunomoduladores. | |
DK3584632T3 (da) | Medicinsk lasersystem | |
DK3713727T3 (da) | Fremgangsmåde til forarbejdning af pladeformige emner | |
DK3559737T3 (da) | Terahertz-laserkilde og fremgangsmåde til udsendelse af terahertzstrålinger | |
EP3655806C0 (en) | MODULAR SYSTEM FOR THE SAFE AND CONTROLLED ARRANGEMENT OF OPTICAL FIBERS AND COMPONENTS OF AN OPTICAL SYSTEM |